Russia's First BioPharma Public-Private Partnership Eyes Bio-Betters, Attracts $110 Million

Russia's bid to catch up in the global race to establish a recognized biopharma sector picked up speed with the Aug. 4 announcement of SynBio, a $110 million joint venture to develop bio-betters and innovative medicines for the Russian and international markets

More from Archive

More from Scrip